VIROLOGIC AND IMMUNOLOGIC EFFECTS OF ADDING ABACAVIR TO HIV PATIENTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的如下： 第一章 （病毒学），以确定添加阿巴卡韦是否会降低使用茚地那韦和依法韦仑实现病毒抑制的受试者中的病毒复制; （二） （病毒学）估计加入阿巴卡韦后游离病毒的衰减率; 第三章 （免疫学）描述持续病毒抑制4年的患者队列中的HIV免疫应答; 四、 （免疫学），以确定是否增加和/或放大的HIV免疫反应时，观察到的抗逆转录病毒治疗与阿巴卡韦增强。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are as follows: 1) (Virologic) to determine if the addition of abacavir decreases viral replication in subjects with viral suppression achieved with indinavir and efavirenz; 2) (Virologic) to estimate the decay rate of free virus after the addition of abacavir; 3) (Immunologic) to characterize HIV immune responses in a cohort of patients with sustained viral suppression for 4 years; 4) (Immunologic) to determine if increased and/or amplified HIV immune responses are observed when antiretroviral therapy is augmented with abacavir.